A review published in Frontiers examines how Regulation (EU) 2019/6 — the framework governing veterinary medicines across the European Union — has shaped innovation in animal health, and sets out recommendations for improving the system.

The paper, titled "Innovation in animal health under Regulation (EU) 2019/6: Review and recommendations," analyzes the regulatory environment that now controls the authorization, manufacture, distribution, and pharmacovigilance of veterinary medicinal products in all EU member states. Its central question is practical: does the current framework encourage or constrain the development of new animal health products, and where should policymakers intervene next?

Why does this regulation matter to practitioners?

Regulation (EU) 2019/6 replaced the previous EU medicines directive and introduced a single market framework for veterinary medicinal products. For veterinary practices, the rules touch daily realities: which products reach the market, how quickly generic and biosimilar medicines become available, how antimicrobials are prescribed, and how pharmacovigilance obligations are handled at clinic level.

The Frontiers review frames innovation broadly — covering novel pharmaceuticals, vaccines, and alternative products — and evaluates whether the regulation's provisions translate into a workable pathway for companies developing them.

What does the review cover?

The authors structure their analysis around the regulation's core mechanisms:

• Marketing authorization pathways, including centralized and decentralized procedures that determine how quickly a product can reach multiple member states.
• Data protection and exclusivity periods, which shape the commercial incentive to develop new veterinary medicines, especially for minor species and limited-market indications.
• Antimicrobial provisions, reflecting the regulation's public-health aim of restricting antimicrobial use in animals to preserve efficacy for human medicine.
• Pharmacovigilance requirements, which impose monitoring duties on companies and competent authorities after a product reaches the market.
• Availability and shortage management, a recurring EU concern that directly affects what clinics can stock and prescribe.

For food-animal veterinarians, the antimicrobial and availability provisions carry the greatest practical weight. For companion-animal practice, exclusivity rules and authorization timelines influence how soon new therapies — including niche and specialist products — reach the market. Public-health implications run through the regulation's One Health orientation, linking veterinary drug policy to antimicrobial resistance control in humans.

What changes at the exam table or in the barn?

The review's relevance to clinical practice is indirect but concrete. Regulatory friction that delays authorization or discourages investment in minor-use products produces gaps on the shelf — fewer options for rare diseases, non-food-producing species, and conditions with small patient populations. Conversely, streamlined pathways for generics and biosimilars can expand access and apply downward pressure on price.

By assessing where the regulation succeeds and where it stalls, the authors aim to give regulators, industry, and the veterinary profession a common evidence base for the next round of policy refinement.

What are the recommendations?

The paper concludes with recommendations addressed to policymakers and stakeholders. These focus on aligning the regulatory framework with the realities of animal health product development — ensuring that incentives, procedures, and post-market obligations work together rather than at cross-purposes. The authors argue that innovation in animal health depends not only on scientific progress but on a regulatory architecture that makes it feasible to bring safe, effective products to animals in the EU.

What comes next?

The review arrives as the regulation matures into its implementation phase, giving EU institutions and national competent authorities a timely assessment as they weigh adjustments to the framework. Veterinarians, industry, and regulators will be watching whether its recommendations inform future amendments, guidance documents, and technical implementing measures under Regulation (EU) 2019/6.